218 related articles for article (PubMed ID: 14514747)
1. Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate.
Coco M; Glicklich D; Faugere MC; Burris L; Bognar I; Durkin P; Tellis V; Greenstein S; Schechner R; Figueroa K; McDonough P; Wang G; Malluche H
J Am Soc Nephrol; 2003 Oct; 14(10):2669-76. PubMed ID: 14514747
[TBL] [Abstract][Full Text] [Related]
2. Pamidronate used to attenuate post-renal transplant bone loss is not associated with renal dysfunction.
Lee S; Glicklich D; Coco M
Nephrol Dial Transplant; 2004 Nov; 19(11):2870-3. PubMed ID: 15466880
[TBL] [Abstract][Full Text] [Related]
3. Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study.
Krieg MA; Seydoux C; Sandini L; Goy JJ; Berguer DG; Thiébaud D; Burckhardt P
Osteoporos Int; 2001; 12(2):112-6. PubMed ID: 11303710
[TBL] [Abstract][Full Text] [Related]
4. Pamidronate therapy as prevention of bone loss following renal transplantation.
Fan SL; Almond MK; Ball E; Evans K; Cunningham J
Kidney Int; 2000 Feb; 57(2):684-90. PubMed ID: 10652047
[TBL] [Abstract][Full Text] [Related]
5. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.
Dodidou P; Bruckner T; Hosch S; Haass M; Klar E; Sauer P; Ziegler R; Leidig-Bruckner G
Osteoporos Int; 2003 Jan; 14(1):82-9. PubMed ID: 12577189
[TBL] [Abstract][Full Text] [Related]
6. Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation.
Ninkovic M; Love S; Tom BD; Bearcroft PW; Alexander GJ; Compston JE
J Hepatol; 2002 Jul; 37(1):93-100. PubMed ID: 12076867
[TBL] [Abstract][Full Text] [Related]
7. The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis.
Vis M; Bultink IE; Dijkmans BA; Lems WF
Osteoporos Int; 2005 Nov; 16(11):1432-5. PubMed ID: 15883662
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation.
Aris RM; Lester GE; Renner JB; Winders A; Denene Blackwood A; Lark RK; Ontjes DA
Am J Respir Crit Care Med; 2000 Sep; 162(3 Pt 1):941-6. PubMed ID: 10988110
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of low doses of pamidronate in osteopenic patients administered in the early post-renal transplant.
Torregrosa JV; Fuster D; Monegal A; Gentil MA; Bravo J; Guirado L; Muxí A; Cubero J
Osteoporos Int; 2011 Jan; 22(1):281-7. PubMed ID: 20229199
[TBL] [Abstract][Full Text] [Related]
10. Bone mineral density in lung-transplant recipients before and after graft: prevention of lumbar spine post-transplantation-accelerated bone loss by pamidronate.
Trombetti A; Gerbase MW; Spiliopoulos A; Slosman DO; Nicod LP; Rizzoli R
J Heart Lung Transplant; 2000 Aug; 19(8):736-43. PubMed ID: 10967266
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease.
Bartram SA; Peaston RT; Rawlings DJ; Francis RM; Thompson NP
Aliment Pharmacol Ther; 2003 Dec; 18(11-12):1121-7. PubMed ID: 14653832
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects on bone mineral density of pamidronate given at the time of renal transplantation.
Fan SL; Kumar S; Cunningham J
Kidney Int; 2003 Jun; 63(6):2275-9. PubMed ID: 12753318
[TBL] [Abstract][Full Text] [Related]
13. Low-dose pamidronate for treatment of early bone loss following kidney transplantation: a randomized controlled trial.
Shahidi S; Ashrafi F; Mohammadi M; Moeinzadeh F; Atapour A
Iran J Kidney Dis; 2015 Jan; 9(1):50-5. PubMed ID: 25599737
[TBL] [Abstract][Full Text] [Related]
14. Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial.
Monegal A; Guañabens N; Suárez MJ; Suárez F; Clemente G; García-González M; De la Mata M; Serrano T; Casafont F; Tome S; Barrios C; Navasa M
Transpl Int; 2009 Feb; 22(2):198-206. PubMed ID: 18796000
[TBL] [Abstract][Full Text] [Related]
15. Comparison of alendronate and pamidronate on bone loss in kidney transplant patients for the first 6 months of transplantation.
Omidvar B; Ghorbani A; Shahbazian H; Beladi Mousavi SS; Shariat Nabavi SJ; Alasti M
Iran J Kidney Dis; 2011 Nov; 5(6):420-4. PubMed ID: 22057076
[TBL] [Abstract][Full Text] [Related]
16. Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate.
Bianda T; Linka A; Junga G; Brunner H; Steinert H; Kiowski W; Schmid C
Calcif Tissue Int; 2000 Aug; 67(2):116-21. PubMed ID: 10920215
[TBL] [Abstract][Full Text] [Related]
17. Pamidronate and osteoporosis prevention in liver transplant recipients.
Pennisi P; Trombetti A; Giostra E; Mentha G; Rizzoli R; Fiore CE
Rheumatol Int; 2007 Jan; 27(3):251-6. PubMed ID: 16944154
[TBL] [Abstract][Full Text] [Related]
18. Individualized therapy to prevent bone mineral density loss after kidney and kidney-pancreas transplantation.
Mainra R; Elder GJ
Clin J Am Soc Nephrol; 2010 Jan; 5(1):117-24. PubMed ID: 19965527
[TBL] [Abstract][Full Text] [Related]
19. Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial.
Fahrleitner-Pammer A; Piswanger-Soelkner JC; Pieber TR; Obermayer-Pietsch BM; Pilz S; Dimai HP; Prenner G; Tscheliessnigg KH; Hauge E; Portugaller RH; Dobnig H
J Bone Miner Res; 2009 Jul; 24(7):1335-44. PubMed ID: 19257824
[TBL] [Abstract][Full Text] [Related]
20. Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation.
Reeves HL; Francis RM; Manas DM; Hudson M; Day CP
Liver Transpl Surg; 1998 Sep; 4(5):404-9. PubMed ID: 9724478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
